{"id":34277,"date":"2018-10-12T09:00:00","date_gmt":"2018-10-12T07:00:00","guid":{"rendered":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-to-present-new-data-from-its-oncology-portfolio-at-the-2018-european-society-for-medical-oncology-esmo-congress\/"},"modified":"2018-10-12T09:00:00","modified_gmt":"2018-10-12T07:00:00","slug":"ipsen-to-present-new-data-from-its-oncology-portfolio-at-the-2018-european-society-for-medical-oncology-esmo-congress","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-to-present-new-data-from-its-oncology-portfolio-at-the-2018-european-society-for-medical-oncology-esmo-congress\/","title":{"rendered":"Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress"},"content":{"rendered":"

Paris (France), 12 October 2018 \u2013\u00a0<\/b>Ipsen (Euronext: IPN; ADR: IPSEY) today announced that cabozantinib (Cabometyx\u00ae), irinotecan liposome injection (Onivyde\u00ae), lanreotide (Somatuline\u00ae) and the combination of lanreotide and telotristat (Xermelo\u00ae) are the subject of 12 presentations at the 2018 European Society for Medical Oncology (ESMO) annual congress. The meeting takes place in Munich, Germany, October 19-23, 2018.<\/p>\n

\u201cIpsen has had a momentous 12 months since ESMO 2017, particularly with the positive regulatory milestones achieved for Cabometyx<\/em>\u00ae<\/em>\u00a0in renal cell and hepatocellular carcinoma, and for Xermelo<\/em>\u00ae\u00a0<\/em>in neuroendocrine tumours. Our story continues with a strong presence at ESMO 2018 with 12 posters presenting\u00a0<\/em>meaningful data for patients with\u00a0<\/em>hepatocellular carcinoma, renal cell carcinoma, medullary thyroid cancer, pancreatic cancer and neuroendocrine tumours<\/em>,\u201d said\u00a0Alexandre Lebeaut M.D, Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen.<\/b>
\u201cOur oncology products, notably Cabometyx\u00ae, Onivyde\u00ae, Somatuline\u00ae\u00a0and Xermelo\u00ae\u00a0have been evaluated by scientific teams around the world; either directly by investigators, by our partners, or by Ipsen, and results from some of these investigations will be shared at ESMO 2018. We are committed in our efforts against cancer, and through our interactions at ESMO will continue to advance innovation for patient care in oncology\u201d,\u00a0<\/em>added\u00a0Dr Lebeaut<\/b>.<\/b>
<\/em><\/em><\/p>\n

Cabozantinib (Cabometyx<\/u><\/b>\u00ae<\/u><\/b>) will be featured in 5 \u00a0posters:<\/u><\/b>
Poster session, Sunday October 21<\/u>st<\/u>, 13:15\u00a0<\/u><\/em>\u2010<\/u><\/em>\u00a014:15, Hall A3<\/u><\/em><\/em>
\u00a0CELESTIAL study<\/em><\/em><\/p>\n